Replimune Group Files Q3 2024 10-Q
Ticker: REPL · Form: 10-Q · Filed: 2025-02-12T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, biotechnology, financials
TL;DR
Replimune's Q3 10-Q is in, check financials for latest performance.
AI Summary
Replimune Group, Inc. filed its 10-Q for the period ending December 31, 2024. The company, based in Woburn, MA, operates in the biological products sector. This filing covers their third fiscal quarter, with financial data for the periods ending December 31, 2024, and December 31, 2023, as well as comparative data for earlier quarters.
Why It Matters
This filing provides investors with the latest financial performance and operational updates for Replimune Group, Inc., crucial for understanding the company's current standing and future prospects.
Risk Assessment
Risk Level: medium — As a biotechnology company, Replimune faces inherent risks related to drug development, clinical trials, and regulatory approvals.
Key Players & Entities
- Replimune Group, Inc. (company) — Filer of the 10-Q
- 2024-12-31 (date) — End of reporting period
- Woburn, MA (location) — Company headquarters
- 2025-02-12 (date) — Filing date
FAQ
What is the reporting period for this 10-Q filing?
The 10-Q filing is for the period ending December 31, 2024.
When was this 10-Q filed with the SEC?
This 10-Q was filed on February 12, 2025.
What is Replimune Group, Inc.'s primary business sector?
Replimune Group, Inc. is in the BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) sector.
What is the company's fiscal year end?
Replimune Group, Inc.'s fiscal year ends on March 31.
What fiscal quarter does this filing represent?
This filing represents the third fiscal quarter (Q3) of the fiscal year.
Filing Stats: 4,711 words · 19 min read · ~16 pages · Grade level 16.3 · Accepted 2025-02-12 08:07:39
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share REPL The Nasdaq Stock Market
Filing Documents
- repl-20241231.htm (10-Q) — 1487KB
- repl-12312024x10qxex311.htm (EX-31.1) — 11KB
- repl-12312024x10qxex312.htm (EX-31.2) — 10KB
- repl-12312024x10qxex321.htm (EX-32.1) — 5KB
- repl-12312024x10qxex322.htm (EX-32.2) — 5KB
- 0001737953-25-000004.txt ( ) — 7286KB
- repl-20241231.xsd (EX-101.SCH) — 56KB
- repl-20241231_cal.xml (EX-101.CAL) — 87KB
- repl-20241231_def.xml (EX-101.DEF) — 200KB
- repl-20241231_lab.xml (EX-101.LAB) — 673KB
- repl-20241231_pre.xml (EX-101.PRE) — 456KB
- repl-20241231_htm.xml (XML) — 914KB
FINANCIAL INFORMATION
PART I FINANCIAL INFORMATION 3 Item 1. Condensed Consolidated Financial Statements (Unaudited) 3 Condensed Consolidated Balance Sheets 3 Condensed Consolidated Statements of Operations 4 Condensed Consolidated Statements of Comprehensive Loss 5 Condensed Consolidated Statements of Stockholders' Equity 6 Condensed Consolidated Statements of Cash Flows 7 Notes to Unaudited Condensed Consolidated Financial Statements 8 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 24 Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 39 Item 4.
Controls and Procedures
Controls and Procedures 39
OTHER INFORMATION
PART II OTHER INFORMATION 40 Item 1.
Legal Proceedings
Legal Proceedings 40 Item 1A.
Risk Factors
Risk Factors 40 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 76 Item 3. Defaults Upon Senior Securities 76 Item 4. Mine Safety Disclosure 76 Item 5. Other Information 76 Item 6. Exhibits 76
SIGNATURES
SIGNATURES 78 2 Table of Contents
- FINANCIAL INFORMATION
PART I - FINANCIAL INFORMATION
Financial Statements
Item 1. Financial Statements. REPLIMUNE GROUP, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (Amounts in thousands, except share and per share amounts) (Unaudited) December 31, 2024 March 31, 2024 Assets Current assets: Cash and cash equivalents $ 172,245 $ 74,457 Short-term investments 364,294 346,211 Research and development incentives receivable 3,066 4,922 Prepaid expenses and other current assets 7,972 8,077 Total current assets 547,577 433,667 Property, plant and equipment, net 13,616 10,483 Restricted cash 1,700 1,700 Other non-current assets 1,200 — Right-to-use asset - operating leases 4,120 4,635 Right-to-use asset - financing leases 35,415 37,237 Total assets $ 603,628 $ 487,722 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 7,188 $ 2,578 Accrued expenses and other current liabilities 36,759 33,981 Operating lease liabilities, current 1,164 1,161 Financing lease liabilities, current 2,779 2,718 Total current liabilities 47,890 40,438 Operating lease liabilities, non-current 3,225 3,771 Financing lease liabilities, non-current 22,913 23,410 Long term debt, net of discount 45,960 44,809 Other liabilities, non-current 1,266 786 Total liabilities $ 121,254 $ 113,214 Commitments and contingencies (Note 14) Stockholders' equity Common stock, $ 0.001 par value; 150,000,000 shares authorized as of December 31, 2024 and March 31, 2024; 77,009,058 and 61,415,105 shares issued and outstanding as of December 31, 2024 and March 31, 2024, respectively 77 61 Additional paid-in capital 1,350,587 1,070,874 Accumulated deficit ( 874,449 ) ( 701,282 ) Accumulated other comprehensive income 6,159 4,855 Total stockholders' equity 482,374 374,508 Total liabilities and stockholders' equity $ 603,628 $ 487,722 The accompanying notes are an integral part of these condensed consolidated financial statements. 3 Table of Contents REPLIMUNE GROUP, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Amo